Deutsche Bank AG reaffirmed their buy rating on shares of BTG plc (LON:BTG) in a research report released on Friday morning. Deutsche Bank AG currently has a GBX 775 ($10.19) target price on the stock.
Several other equities analysts have also issued reports on BTG. Numis Securities Ltd reaffirmed a buy rating and set a GBX 900 ($11.83) price objective on shares of BTG plc in a report on Wednesday, June 14th. J P Morgan Chase & Co reaffirmed a neutral rating and set a GBX 790 ($10.39) price objective on shares of BTG plc in a report on Tuesday, July 4th. Shore Capital reaffirmed a not rated rating on shares of BTG plc in a report on Thursday, July 13th. Stifel Nicolaus reaffirmed a buy rating and set a GBX 800 ($10.52) price objective on shares of BTG plc in a report on Wednesday, August 30th. Finally, Peel Hunt reaffirmed a hold rating and set a GBX 680 ($8.94) price objective on shares of BTG plc in a report on Wednesday, September 20th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of Buy and an average target price of GBX 780.33 ($10.26).
Shares of BTG plc (LON BTG) opened at 703.50 on Friday. BTG plc has a 52-week low of GBX 528.36 and a 52-week high of GBX 738.50. The firm’s market cap is GBX 2.71 billion. The stock has a 50 day moving average price of GBX 684.03 and a 200-day moving average price of GBX 665.00.
TRADEMARK VIOLATION WARNING: This report was originally reported by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://baseballnewssource.com/markets/btg-plc-btg-rating-reiterated-by-deutsche-bank-ag/1702925.html.
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with our FREE daily email newsletter.